Is IGC Pharma, Inc. overvalued or undervalued?

As of 10 August 2023, IGC Pharma, Inc. has moved from a grade of "does not qualify" to "risky." The company is currently considered overvalued based on its financial metrics. Key ratios include a Price to Book Value of 3.90, an EV to EBIT of -2.95, and an EV to EBITDA of -3.21, all indicating significant financial distress.
In comparison to its peers, IGC Pharma's EV to EBITDA ratio is notably worse than Pieris Pharmaceuticals, which stands at -9.60, and OncoCyte Corp., which is at -2.86, both of which are also classified as risky. The company's return performance has lagged significantly behind the S&P 500, with a one-year return of -44.47% compared to the index's 10.26%. These factors collectively suggest that IGC Pharma, Inc. is overvalued in its current state.